Conexeu Sciences Inc. (NASDAQ:CNXU – Get Free Report) Director Lynn Sebastian Purcell bought 202,500 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were acquired at an average cost of $0.80 per share, with a total value of $162,000.00. Following the acquisition, the director directly owned 2,734,240 shares of the company’s stock, valued at approximately $2,187,392. This represents a 8.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Conexeu Sciences Stock Up 1.3%
Shares of NASDAQ CNXU opened at $10.69 on Thursday. Conexeu Sciences Inc. has a 52 week low of $9.60 and a 52 week high of $18.79.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the company. HC Wainwright assumed coverage on Conexeu Sciences in a research report on Monday. They issued a “buy” rating and a $20.00 price target for the company. Wall Street Zen upgraded Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $20.00.
Conexeu Sciences Company Profile
Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.
See Also
- Five stocks we like better than Conexeu Sciences
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Conexeu Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conexeu Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
